Lakatos P, Tóth E, Szekeres L, Poór G, Héjj G, Marton I, Takács I
1st Department of Medicine, Semmelweis University, Korányi u. 2/A, Budapest, 1083, Hungary.
Osteoporos Int. 2014 Aug;25(8):2077-87. doi: 10.1007/s00198-014-2733-2. Epub 2014 May 13.
The efficacy of interventions used in real life for the treatment of osteoporosis has not been evaluated on a national basis. We analysed the database of the single Hungarian health care provider between 2004 and 2010. A marked reduction in fracture incidence and hospitalization was seen, which also proved to be cost-effective.
Osteoporosis and its consequences place a significant burden on the health care systems of developed countries. Present therapeutic modalities are effective in reducing the risk of fractures caused by osteoporosis. However, we do not know whether the interventions introduced in the past 15 years have significantly reduced the number of osteoporotic fractures in real life, and if yes, how cost-effectively.
The database of the National Health Insurance Fund Administration in Hungary was analysed for the period between 2004 and 2010. Two specific patient groups were identified within the population. Patients, who were under osteoporosis treatment in more than 80% of the potential treatment days in three consecutive years (patients with high compliance), were compared with patients where this ratio was under 20% (patients with low compliance). Several statistical comparative models were implemented in order to capture a complete picture on the differences. Because of natural data heterogeneity of administration databases, propensity matching was applied as well.
Comparing treated vs. control subjects, patients with high compliance showed a significant decrease in fracture risk and hospitalization, which was more robust after propensity adjustment. On the basis of the observed statistically significant differences, cost-effectiveness analysis was implemented. Utility loss due the observed fractures was compared with the total cost differences of the two arms based on modelling. Our calculations proved the cost-effectiveness of the long-term high compliance in real world settings.
Our findings infer that the standardized and uniform health care of osteoporotic patients in a country may reduce general fracture incidence and hospitalization in a cost-effective way.
现实生活中用于治疗骨质疏松症的干预措施的疗效尚未在全国范围内进行评估。我们分析了匈牙利单一医疗服务提供商在2004年至2010年期间的数据库。结果发现骨折发生率和住院率显著降低,且证明具有成本效益。
骨质疏松症及其后果给发达国家的医疗保健系统带来了沉重负担。目前的治疗方式在降低骨质疏松症所致骨折风险方面是有效的。然而,我们不知道过去15年引入的干预措施在现实生活中是否显著减少了骨质疏松性骨折的数量,如果是,其成本效益如何。
分析了匈牙利国家健康保险基金管理局2004年至2010年期间的数据库。在人群中确定了两个特定患者组。将连续三年中80%以上潜在治疗天数接受骨质疏松症治疗的患者(高依从性患者)与该比例低于20%的患者(低依从性患者)进行比较。实施了几种统计比较模型以全面了解差异情况。由于管理数据库存在自然数据异质性,因此也应用了倾向匹配法。
比较治疗组与对照组,高依从性患者的骨折风险和住院率显著降低,倾向调整后更为显著。基于观察到的统计学显著差异,进行了成本效益分析。根据模型将观察到的骨折导致的效用损失与两组的总成本差异进行比较。我们的计算证明了现实世界中长期高依从性的成本效益。
我们的研究结果表明,一个国家对骨质疏松症患者进行标准化和统一的医疗保健可能以具有成本效益的方式降低总体骨折发生率和住院率。